RxDoctor Payments DataLook up a doctor →

Eve Gillespie, MD

Cardiovascular Disease · Kalispell, MTNPI 1922038520

Payments from drug & device makers

$1,404,820in general payments, 2019–2025

Across 531 payments — averaging $2645.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$296K
  • Merck$271K
  • Novartis$261K
  • Amgen$217K
  • Bayer$135K
  • Esperion Therapeutics, Inc.$124K
  • plus $102K from 17 others

What the payments were for

  • Food & beverage$1,17397%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,404,820 in reported general payments places this provider in the 95th percentile of 49 cardiovascular disease providers in Montana.

See all cardiovascular disease providers in Montana

Medicare billing

Part B allowed, 2024
$146,778
Medicare patients
674
Services billed
1,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban321$301,579
VyndaqelTafamidis Meglumine11$245,655
EntrestoSacubitril/Valsartan253$235,140
XareltoRivaroxaban101$116,012
Repatha SureclickEvolocumab82$56,848
JardianceEmpagliflozin31$31,511
Praluent PenAlirocumab47$23,229
VerquvoVericiguat16$18,726
CorlanorIvabradine Hcl16$8,306
Metoprolol Succinate575$7,916
Dabigatran EtexilateDabigatran Etexilate Mesylate41$6,612
Ezetimibe216$5,041
PradaxaDabigatran Etexilate Mesylate20$5,012
Potassium Chloride246$4,708
Atorvastatin Calcium370$3,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$260,552$235,140253 claims
Johnson & JohnsonXarelto$140$116,012101 claims
Boehringer IngelheimJardiance, Pradaxa$165$36,52351 claims
MerckVerquvo$270,558$18,72616 claims
AmgenCorlanor$216,945$8,30616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 cardiovascular disease providers in Montana.

Other cardiovascular disease in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →